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Alternating hemiplegia of childhood (AHC) is a very rare neuro­
developmental disorder, with an estimated incidence of 1 in 
1 000 000.[1] The presentation can be highy variable, but the seven 
accepted diagnostic criteria are as follows: (i) onset before 18 months 
of age; (ii) repeated episodes of hemiplegia involving the right or 
left side of the body, at least in some episodes; (iii) episodes of 
quadriplegia, starting directly or as generalisation of a hemiplegic 
episode; (iv) other paroxysmal disturbances, including tonic/dystonic 
attacks, nystagmus, strabismus, dyspnoea, and other autonomic 
phenomena occurring during hemiplegic attacks or in isolation; 
(v) immediate disappearance of all symptoms on going to sleep, 
with recurrence 10 ­ 20 minutes after awakening; (vi) evidence of 
developmental delay, learning disability, neurological abnormalities, 
choreoathetosis, dystonia or ataxia; and (vii) not attributable to 
another disorder.[1­3] The diagnosis of AHC was previously based 
solely on clinical manifestations, but in 2012 mutations in the 
ATP1A3 gene encoding the sodium­potassium ATPase α3 subunit 
were identified as the primary genetic cause of the disease.[4] In recent 
years it has also become apparent that this clinical entity is probably 
part of a wider spectrum of disorders seen with these mutations. The 
other well­described conditions included in this spectrum are rapid­
onset dystonia parkinsonism and CAPOS syndrome (cerebellar 
ataxia, areflexia, pes cavus, optic atrophy and sensorineural hearing 
loss). These conditions are therefore sometimes collectively referred 
to as ATP1A3­related disorders.[4­6]
Management of AHC is challenging and no specific treatment 
exists.[1­3] The aim of treatment is to reduce the frequency and severity 
of the episodes, and to manage them when they occur. Avoiding 
triggers can be helpful if any have been identified, but generally 
patients need long­term drug therapy.[1] A range of therapies have 
shown some promise, but the currently accepted first­line therapy 
is flunarizine, a calcium­channel blocker.[1­3,7­10] This is largely based 
on a case series by Mikati et al.[11] where treatment with flunarizine 
resulted in a 78% reduction in duration, severity and frequency 
of hemiplegic episodes. Subsequent studies have shown similarly 
positive results, if not as impressive.[12] Unfortunately flunarizine 
is not readily available in South Africa (SA). An alternative that 
has shown some promise is topiramate, especially in the setting 
of concomitant epilepsy or migraine.[7] In SA topiramate is only 
available as a patient­motivated drug in the public healthcare sector. 
Furthermore, a thorough literature search revealed no previous 
publications on AHC in SA. Managing this unique disorder is 
therefore challenging in our context. The following case report aims 
to provide some illumination.
Case report
A 5­year­old boy was referred to the paediatric neurology clinic at 
Frere Hospital, East London, with poorly controlled epilepsy and 
developmental delay. The seizure morphology was described by 
the mother, who reported that the child would have unprovoked, 
sudden­onset paralysis of one side of the body. At times this would 
start by only affecting one arm, but as the episode continued the 
paralysis would spread to the ipsilateral leg. The boy would remain 
fully alert, and would be able to talk, eat and – with less severe 
episodes – walk. These episodes would last a variable amount of time 
lasting from a few hours to up to 5 days, and would then resolve 
completely with no residual effects. No urinary or faecal incontinence 
occurred. The frequency of the episodes was unpredictable, ranging 
from several times a week to only once a month. Occasionally both 
sides of the body would be involved (quadriplegia) and dystonic 
hand movements were reported. Notably, the mother revealed that 
the paralysis would resolve if the child went to sleep during these 
episodes and would return 15 ­ 20 minutes after waking.
The medical history revealed that the child was diagnosed with 
epilepsy at the age of 7 months (when these episodes began) and 
was treated with an array of antiepileptic drugs. By the age of 5, 
high­dose phenobarbitone (7 mg/kg/d), high­dose sodium valproate 
(30 mg/kg/d), carbamazepine and clonazepam had been tried, with 
no improvement. In over 4 years, the longest asymptomatic period 
was less than 2 months and the drugs had no effect on the duration or 
severity of episodes once they occurred. The only family history was 
that the child’s mother was known to have myasthenia gravis. He had 
started preschool, but could not cope and had been removed owing to 
what the school had labelled as uncontrolled epilepsy.
On examination, he appeared as a friendly young boy with global 
developmental delay. He had no dysmorphic features. His weight, 
height and head circumference were between 0 and –1 z­scores. He 
spoke in short sentences and was able to perform simple tasks. He 
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was noted to be hyperactive and was not able to sit down to copy 
shapes. On further examination he had strabismus, a normal gait, 
normal power, normal muscular tone and normal reflexes. He was 
unable to hop or stand on one leg and was unable to follow the 
instructions for the diadochokinesis or finger­nose tests. All other 
systems were unremarkable. Previous work­up for the presumed 
diagnosis of epilepsy included basic blood investigations, lumbar 
puncture, an electroencephalogram and a computed tomography 
scan of the brain, which were all normal.
Based on the boy’s history, the clinical findings and the results of 
the special investigations, he met all of the seven accepted criteria 
and was diagnosed with AHC. Unfortunately genetic testing for the 
ATP1A3 mutation is not available in SA. All the anticonvulsants were 
stopped, and as flunarizine is not available in SA and topiramate 
could only be obtained through a patient­named motivation, it was 
decided to start him on verapamil in the interim. Verapamil was 
largely chosen because of its availability and similar mechanism 
of action to flunarizine, and it had shown some positive results in 
previous cases.[9]
One month later, after the verapamil dose had been slowly 
increased to 6.6 mg/kg/d in three divided doses, the boy was 
tolerating the treatment well with no adverse effects. Over the next 
6 months there was a marked reduction in the frequency, severity 
and duration of the hemiplegic episodes. Episodes only occurred 
about once a month, the extent of the paralysis with each episode 
was less severe, and symptoms would always resolve in less than 24 
hours. Owing to the improved control of his episodes he was able to 
enrol successfully in a special­needs school. His continued progress 
is currently being closely monitored.
Discussion
This is the first case report of AHC in SA. An interesting aspect is the 
diagnosis of AHC in a black African child. Previous publications on 
AHC do not always disclose the ethnicity of the participants, but the 
vast majority of patients were from European and American centres, 
which may suggest that the diagnosis, and the ATP1A3 mutation, 
are very rare in the black population. The other element of note is 
the perceived efficacy of verapamil as a treatment option for AHC. 
The marked reduction in episode frequency, severity and duration 
reported by the caregiver, a 6­month period free of major debilitating 
episodes and the subsequent enrolment in a special­needs school 
suggest that verapamil could be a viable alternative in treating AHC 
in the SA setting.
Informed consent to publication of this case report was obtained 
from the guardian of the patient.
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